Uso de canabinóides na dor crônica e em cuidados paliativos

Abstract

Pure delta-9-tetrahydrocannabinol (Delta9-THC) and its analogues have clinical applicability, being beneficial in selected individuals. The development of pure synthetic substances, in an attempt to attenuate undesirable psychoactive effects, indicates that perspectives for its use in the future are favorable. More detailed studies should be undertaken. Ample debates will be necessary to create standards for its formulation and clinical availability, since it is a substance that generates prejudice, due to its illegal commercialization and use, and also because its use has been attributed to mysticism.

Eficácia do canabidiol no tratamento de convulsões e doenças do sistema nervoso central: revisão sistemática

“…O efeito anticonvulsivante do canabidiol é promissor, justificando a sua inclusão no arsenal terapêutico porque possui efeito antiepiléptico reconhecido. Para isto, a cada ano estão sendo realizados novos testes de ensaio clínicos com metodologias variadas, que pretendem elucidar tudo aquilo que se mantém vago, no que tange à segurança na utilização do composto (Bonfá, Vinagre & Figueredo, 2008).…”

Perspectives in veterinary medicine on the use of cannabinoids as complementary palliative therapy for pain in cancer patients

“…The CB1 receptors are located in areas of the cerebellum, basal ganglia, hippocampus, cerebral cortex, spinal cord, and peripheral nerves, and are responsible for the psychotropic effects of endocannabinoids. In contrast, CB2 receptors may be reported in cells of the immune system, T cells, B cells, and spleen and may be in part associated with the modulatory effects in pain and inflammatory responses (BONFÁ et al, 2008;BRUCKI et al, 2015;MURNION, 2015;ABRAMS, 2016;MAIDA & DAENINCK, 2016; TURGEMAN & BAR-SELA, 2017) ( Figure 1).…”

“…Oral spray with active ingredients of THC and cannabidiol (Sativex ® ) underwent clinical trials and was approved for medical prescription. Its use is only allowed in individualized dosage regimens to patients with cancer pain and neuropathic pain (BONFÁ et al, 2008;PAMPLONA, 2014).…”

“…Its medicinal properties have been reported for centuries but only recently it started being prescribed for pain after the discovery of endogenous cannabinoid receptors (BONFÁ et al, 2008;LESSA et al, 2016). Cannabis-based pain medication is currently available in the international market for the use in human patients (PAMPLONA, 2014).…”

Cannabinoid derivatives and the pharmacological management of pain

“…Recently, in Brazil, the controversial discussion about CS for medical use has been intensified due to the need for legal authorization to import cannabidiol for the treatment of children with seizures refractory to conventional therapies. Medical use of CS has been recommended for different clinical conditions for many centuries 1 . In this sense, it is worth stressing that the two most widely used classes of drugs to manage pain (opioids and anti-inflammatory drugs), have vegetal origin.…”